The role of HTS in drug discovery at the university of michigan

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 3, 2014, Pages 210-230

  Larsen, Martha J ^a   Larsen, Scott D ^a   Fribley, Andrew ^b   Grembecka, Jolanta ^c   Homan, Kristoff ^a   Mapp, Anna ^a   Haak, Andrew ^c   Nikolovska Coleska, Zaneta ^c   Stuckey, Jeanne A ^c   Sun, Duxin ^a   Sherman, David H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Drug discovery; High throughput screening; Medicinal chemistry; Pharmacokinetics; Protein crystallography; Structural biology

Indexed keywords

5 (4 CHLORO 3 NITROPHENYL) 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; 5 [4 (2 DIETHYLAMINOETHYLAMINO) 3 NITROPHENYL] 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; AMLEXANOX; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APTAMER; BH3 PROTEIN; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANOSINE TRIPHOSPHATASE; METHIONINE; MI 2 2; MIXED LINEAGE LEUKEMIA PROTEIN; PAROXETINE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RHO KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; MOLECULAR LIBRARY; PROTEIN;

ALPHA VIRUS; ANATOMICAL CONCEPTS; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIODIVERSITY; BIOLOGICAL ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CHEMICAL GENETICS; CLINICAL CHEMISTRY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG REPOSITIONING; FOLLOW UP; GENETIC SCREENING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; STREPTOCOCCUS GROUP A; SYNTHESIS; UNFOLDED PROTEIN RESPONSE; UNITED STATES; VIRUS VIRULENCE; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; X RAY SYSTEM; CHEMISTRY; ISOLATION AND PURIFICATION; MEDICINAL CHEMISTRY; MOLECULAR BIOLOGY; MOLECULAR LIBRARY; ORGANIZATION AND MANAGEMENT; PHARMACOLOGY; PROCEDURES; PROTEIN FOLDING; UNIVERSITY;

BIOLOGICAL PRODUCTS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICHIGAN; MOLECULAR BIOLOGY; PHARMACOKINETICS; PROTEIN FOLDING; PROTEINS; SMALL MOLECULE LIBRARIES; UNIVERSITIES;

EID: 84897994874     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666140109121546     Document Type: Article

References (116)

1. Jacob, R.T.; Larsen, M.J.; Larsen, S.D.; Kirchhoff, P.D.; Sherman, D.H.; Neubig, R.R. MScreen: An integrated compound management and high-throughput screening data storage and analysis system. J. Biomol. Screen., 2012, 17(8), 1080-1087.
2. Reilly, S.M.; Chiang, S.H.; Decker, S.J.; Chang, L.; Uhm, M.; Larsen, M.J.; Rubin, J.R.; Mowers, J.; White, N.M.; Hochberg, I; Downes, M.; Yu, R.T.; Liddle, C.; Evans, R.M.; Oh, D.; Li, P.; Olefsky, J.M.; Saltiel, A.R. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat. Med., 2013, 19(3), 313-321.
3. Olefsky, J.M.; Glass, C.K. Macrophages; inflammation; and insulin resistance. Annu. Rev. Physiol., 2010, 72, 219-246.
4. Chiang, S.H.; Bazuine, M.; Lumeng, C.N.; Geletka, L.M.; Mowers, J.; White, N.M.; Ma, J.T.; Zhou, J.; Qi, N.; Westcott, D.; Delproposto, J.B.; Blackwell, T.S.; Yull, F.E.; Saltiel, A.R. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell, 2009, 138(5), 961-975.
5. Chau, T.L.; Gioia, R.; Gatot, J.S.; Patrascu, F.; Carpentier, I.; Chapelle, J.P.; O'Neill, L.; Beyaert, R.; Piette, J.; Chariot, A. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem. Sci., 2008, 33(4), 171-180.
6. Chariot, A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Bio., 2009, 19(8), 404-413.
7. Noha, S.M.; Atanasov A.G.; Schuster D.; Markt P.; Fakhrudin N.; Heiss E.H.; Schrammel O.; Rollinger J.M.; Stuppner H.; Dirsch V.M.; Wolber, G. Discovery of a novel IKK-beta inhibitor by ligand-based virtual screening techniques. Bioorg. Med. Chem. Lett., 2011, 21(1), 577-583.
8. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell, 2010, 142(5), 687-698.
9. Ma, X.; Helgason, E.; Phung, Q.T.; Quan, C.L.; Iyer, R.S.; Lee, M.W.; Bowman, K.K.; Starovasnik, M.A.; Dueber, E.C. Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation. PNAS, 2012, 109(24), 9378-9383.
10. Eschenhagen, T. β-adrenergic signaling in heart failure -adapt or die. Nat. Med., 2008, 14(5), 485-487.
11. Raake, P.W.; Vinge, L.E.; Gao, E.; Boucher, M.; Rengo, G.; Chen, X.; DeGeorge, B.R.J.; Matkovich, S.; Houser, S.R.; Most, P.; Eckhart, A.D.; Dorn, G.W.2nd.; Koch, W.J. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res., 2008, 103(4), 413-422.
12. White, D.C.; Hata, J.A.; Shah, A.S.; Glower, D.D.; Lefkowitz, R.J.; Koch, W.J. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. PNAS, 2000, 97(10), 5428-5433.
13. Rockman, H.A.; Chien, K.R.; Choi, D.J.; Iaccarino, G.; Hunter, J.J.; Ross, J.J.; Lefkowitz, R.J.; Koch, W.J. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. PNAS, 1998, 95(12), 7000-7005.
14. Shah, A.S.; White, D.C.; Emani, S.; Kypson, A.P.; Lilly, R.E.; Wilson, K.; Glower D.D.; Lefkowitz R.J.; Koch W.J. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation, 2001, 103(9), 1311-1316.
15. Rengo, G.; Lymperopoulos, A.; Zincarelli, C.; Donniacuo, M.; Soltys, S.; Rabinowitz, J.E.; Koch, W.J. Myocardial adeno-associated virus serotype 6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation, 2009, 119(1), 89-98.
16. Mayer G.; Wulffen B.; Huber C.; Brockmann J.; Flicke B.; Neumann L.; Hafenbradl D.; Klebl B.M.; Lohse M.J.; Krasel C.; Blind, M. An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro. RNA. 2008, 14(3), 524-534.
17. Hafner, M.; Vianini, E.; Albertoni, B.; Marchetti, L.; Grüne, I.; Gloeckner, C.; Famulok, M. Displacement of protein-bound aptamers with small molecules screened by fluorescence polarization. Nat. Protocol., 2008, 3(4), 579-587.
18. Shankaranarayanan, A.; Thal, D.M.; Tesmer, V.M.; Roman, D.L.; Neubig, R.R.; Kozasa, T.; Tesmer, J.J.G. Assembly of high order Gαqeffector complexes with RGS proteins. J. Biol. Chem., 2008, 283(50), 34923-34934.
19. Edwards, B.S; Zhu, J.; Chen, J.; Carter, M.B.; Thal, D.M.; Tesmer, J.J.G.; Graves, S.W.; Sklar, L.A. Cluster cytometry for high-capacity bioanalysis. Cytometry A., 2012, 81(5), 419-429.
20. Tesmer, V.M.; Lennarz, S.; Mayer, G.; Tesmer, J.J. Molecular mechanism for inhibition of g protein-coupled receptor kinase 2 by a selective RNA aptamer. Structure, 2012, 20(8), 1300-1309.
21. Homan, K.T.; Wu, E.; Wilson, M.W.; Singh, P.; Larsen, S.D.; Tesmer, J.J. Structural and Functional Analysis of G Protein-Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed Analog. Mol. Pharmacol., 2014, 85(2), 237-248..
22. Thal, D.M.; Homan, K.T.; Chen, J.; Wu, E.K.; Hinkle, P.M.; Huang, Z.M.; Chuprun, J.K.; Song, J.; Gao, E.; Cheung, J.Y.; Sklar, L.A.; Koch, W.J.; Tesmer, J.J. Paroxetine is a direct inhibitor of G proteincoupled receptor kinase 2 and increases myocardial contractility. ACS Chem. Biol., 2012, 7(11), 1830-1839.
23. Griffin, D.E.; In, D.M.; Knipe, P.M.H.; Griffin, D.E.; Lamb, R.A; Martin, M.A.; Roizman, B. In: Fields Virology; S.S Straus Ed. Lippincott Williams & Wilkins: Philadelphia, PA, 2001; pp. 917-962.
24. Gubler, D.J. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res., 2002, 33(4), 330-342.
25. Bronze, M.S.; Huycke, M.M.; Machado, L.J.; Voskuhl, G.W.; Greenfield, R.A. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci., 2002, 323(6), 316-325.
26. Sidwell, R.W.; Smee, D.F. Viruses of the Bunya-and Togaviridae families, potential as bioterrorism agents and means of control. Antivir. Res., 2003, 57(1-2), 101-111.
27. NIH/NIAID. Category A; B; & C Priority Pathogens. http, //www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/Pa ges/CatA.aspx [Accessed December 2013].
28. Peng, W.; Peltier, D.C.; Larsen, M.J.; Kirchhoff, P.D.; Larsen, S.D.; Neubig, R.R.; Miller, D.J. Identification of thieno[3;2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses. J. Infect. Dis., 2009, 199(7), 950-957.
29. Sindac, J.A.; Yestrepsky, B.D.; Barraza, S.J.; Bolduc, K.L.; Blakely, P.K.; Keep, R.F.; Irani, D.N.; Miller, D.J.; Larsen, S.D. inhibitors of neurotropic alphavirus replication that improve host survival in a mouse model of acute viral encephalitis. J. Med. Chem., 2012, 55(7), 3535-3545.
30. Jackson, A.C.; Moench, T.R.; Griffin, D.E.; Johnson, R.T. The pathogenesis of spinal cord involvement in the encephalomyelitis of mice caused by neuroadapted Sindbis virus infection. Lab. Invest., 1987, 56(4), 418-423.
31. Jackson, A.C.; Moench, T.R.; Trapp, B.D.; Griffin, D.E. Basis of neurovirulence in Sindbis virus encephalomyelitis of mice. Lab. Invest., 1988, 58(5), 503-509.
32. Garner, A.L.; Janda, K.D. Protein-protein interactions and cancer, targeting the central dogma. Curr. Top. Med. Chem., 2011, 11(3), 258-280.
33. White, A.W.; Westwell, A.D.; Brahemi, G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert. Rev. Mol. Med., 2008, 10, e8.
34. Yokoyama, A.; Somervaille, T.C.; Smith, K.S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell, 2005, 123(2), 207-218.
35. Caslini, C.; Yang, Z.; El-Osta, M.; Milne, T.A.; Slany, R.K.; Hess, J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Canc. Res., 2007, 67(15), 7275-7283.
36. Sorensen, P.H.; Chen, C.S.; Smith, F.O.; Arthur, D.C.; Domer, P.H.; Bernstein, I.D.; Korsmeyer, S.J.; Hammond, G.D.; Kersey, J.H. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J. Clin. Invest., 1994, 93(1), 429-437.
37. Cox, M.C.; Panetta, P.; Lo-Coco, F.; Del Poeta, G.; Venditti, A.; Maurillo, L.; Del Principe, M.I.; Mauriello, A.; Anemona, L.; Bruno, A.; Mazzone, C.; Palombo, P.; Amadori, S. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation, results in 378 adult patients. Am. J. Clin. Pathol., 2004, 122(2), 298-306.
38. Popovic, R.; Zeleznik-Le, N.J. MLL, how complex does it get? J. Cell. Biochem., 2005, 95(2), 234-242.
39. Slany, R.K. When epigenetics kills, MLL fusion proteins in leukemia. Hematol. Oncol., 2005, 23(1), 1-9.
40. Dimartino, J.F; Cleary, M.L. Mll rearrangements in haematological malignancies, lessons from clinical and biological studies. Br. J. Haematol., 1999, 106(3), 614-626.
41. Grembecka, J.; Belcher, A.M.; Hartley, T.; Cierpicki, T. Molecular basis of the mixed lineage leukemia-menin interaction, implications for targeting mixed lineage leukemias. J. Biol. Chem., 2010, 285(52), 40690-40698.
42. Murai, M.J.; Chruszcz, M.; Reddy, G.; Grembecka, J.; Cierpicki, T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem., 2011, 286(36), 31742-31748.
43. Shi, A.; Murai, M.J.; He, S.; Lund, G.; Hartley, T.; Purohit, T.; Reddy, G.; Chruszcz, M.; Grembecka, J.; Cierpicki, T. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood, 2012, 120(23), 4461-4469.
44. Grembecka, J.; He, S.; Shi, A.; Purohit, T.; Muntean, A.G.; Sorenson, R.J.; Showalter, H.D.; Murai, M.J.; Belcher, A.M.; Hartley, T.; Hess, J.L.; Cierpicki, T. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol., 2012, 8(3), 277-284.
45. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
46. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency, a useful metric for lead selection. Drug Discov. Today, 2004, 9(10), 430-431.
47. Higueruelo, A.P.; Schreyer, A.; Bickerton, G.R.; Pitt, W.R.; Groom, C.R.; Blundell, T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces, the TIMBAL database. Chem. Biol. Drug Des., 2009, 74(5), 457-467.
48. Zeisig, B.B.; Milne, T.; Garcia-Cuellar, M.P.; Schreiner, S.; Martin, M.E.; Fuchs, U.; Borkhardt, A.; Chanda, S.K.; Walker, J.; Soden, R.; Hess, J.L.; Slany, R.K. Hoxa9 and Meis1 are key targets for MLLENL-mediated cellular immortalization. Mol. Cell Biol., 2004, 24(2), 617-628.
49. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer, the next generation. Cell, 2011, 144(5), 646-674.
50. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007, 26(9), 1324-1337.
51. Billard, C. BH3 mimetics, status of the field and new developments. Mol. Canc. Therapeut., 2013, 12(9), 1691-1700.
52. Bajwa, N.; Liao, C.; Nikolovska-Coleska, Z. Inhibitors of the antiapoptotic Bcl-2 proteins, a patent review. Expert Opin. Ther. Pat., 2012, 22(1), 37-55.
53. Abulwerdi, F.L.C.; Liu, M.; Azmi, A.S.; Aboukameel, A.; Mady, A.S.; Gulappa, T.; Cierpicki, T.; Owens, S.; Zhang, T.; Sun, D.; Stuckey, J.A.; Mohammad, R.M.; Nikolovska-Coleska, Z. A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In vitro and In vivo. Mol. Cancer Ther., 2014 [Epub ahead of print].
54. Wei, S.H.; Dong, K.; Lin, F.; Wang, X.; Li, B.; Shen, J.J.; Zhang, Q.; Wang, R.; Zhang, H.Z. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother. Pharmacol., 2008, 62(6), 1055-1064.
55. Guoan, X.; Hanning, W.; Kaiyun, C.; Hao, L. Adenovirus-mediated siRNA targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma cells in vitro and in vivo. Surgery, 2010, 147(4), 553-561.
56. Hogberg, L.D.; Heddini, A.; Cars, O. The global need for effective antibiotics, challenges and recent advances. Trends Pharmacol. Sci., 2010, 31(11), 509-515.
57. Rasko, D.A.; Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov., 2010, 9(2), 117-128.
58. Sun, H.; Ringdahl, U.; Homeister, J.W.; Fay, W.P.; Engleberg, N.C.; Yang, A.Y.; Rozek, L.S.; Wang, X.; Sjobring, U; Ginsburg, D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science, 2004, 305(5688), 1283-1286.
59. Sun, H.; Xu, Y.; Sitkiewicz, I.; Ma, Y.; Wang, X.; Yestrepsky, B.D.; Huang, Y.; Lapadatescu, M.C.; Larsen, M.J.; Larsen, S.D.; Musser, J.M.; Ginsburg, D. Inhibitor of streptokinase gene expression improves survival after group A streptococcus infection in mice. PNAS, 2012, 109(9), 3469-3474.
60. Yestrepsky, B.D.; Xu, Y.; Breen, M.E.; Li, X.; Rajeswaran, W.G.; Ryu, J.G.; Sorenson, R.J.; Tsume, Y.; Wilson, M.W.; Zhang, W.; Sun, D.; Sun, H.; Larsen, S.D. Novel inhibitors of bacterial virulence, development of 5;6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. Bioorg. Med. Chem., 2013, 21(7), 1880-1897.
61. Ma, Y.; Xu, Y.; Yestrepsky, B.D.; Sorenson, R.J.; Chen, M.; Larsen, S.D.; Sun, H. Novel inhibitors of Staphylococcus aureus virulence gene expression and biofilm formation. PloS One, 2012, 7(10), e47255.
62. Hanna, S.; El-Sibai, M. Signaling networks of Rho GTPases in cell motility. Cell Signal., 2013, 25(10), 1955-1961.
63. Lu, Q.; Longo, F.M.; Zhou, H.C.; Massa, S.M.; Chen, Y.H. Signaling through Rho GTPase pathway as viable drug target. Curr. Med. Chem., 2009, 16(11), 1355-1365.
64. Miralles, F.; Posern, G.; Zaromytidou, A.I.; Treisman, R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell, 2003, 113(3), 329-342.
65. Medjkane, S.; Perez-Sanchez, C.; Gaggioli, C.; Sahai, E.; Treisman, R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol., 2009, 11(3), 257-268.
66. Evelyn, C.R.; Wade, S.M.; Wang, Q.; Wu, M.; Iniguez-Lluhi, J.A.; Merajver, S.D.; Neubig, R.R. CCG-1423, a small-molecule inhibitor of RhoA transcriptional signaling. Mol. Canc. Therapeut., 2007, 6(8), 2249-2260.
67. Jin, W.; Goldfine, A.B.; Boes, T.; Henry, R.R.; Ciaraldi, T.P.; Kim E.Y.; Emecan, M.; Fitzpatrick, C.; Sen, A.; Shah, A.; Mun, E.; Vokes, V.; Schroeder, J.; Tatro, E.; Jimenez-Chillaron, J.; Patti, M.E. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J. Clin. Investig., 2011, 121(3), 918-929.
68. Sakai, N.; Chun, J.; Duffield, J.S.; Wada, T.; Luster, A.D.; Tager, A.M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J, 2013, 27(5), 1830-1846.
69. Evelyn, C.R.; Bell, J.L.; Ryu, J.G.; Wade, S.M.; Kocab, A.; Harzdorf, N.L.; Hollis Showalter, H.D.; Neubig, R.R.; Larsen, S.D. Design; synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor; CCG-1423. Bioorg. Med. Chem. Lett., 2010, 20(2), 665-672.
70. Bell, J.L.; Haak, A.J.; Wade, S.M.; Kirchhoff, P.D.; Neubig, R.R.; Larsen, S.D. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg. Med. Chem. Lett., 2013, 23(13), 3826-3832.
71. Fidler, M.J.; Basu, S.; Buckingham, L.; Walters, K.; McCormack, S.; Batus, M.; Coon, J.T.; Bonomi, P. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res., 2012, 32(5), 1705-1710.
72. Guha, M. Anticancer IGF1R classes take more knocks. Nat. Rev. Drug. Discov., 2013, 12(4), 250.
73. Steingart, R.M.; Bakris, G.L.; Chen, H.X.; Chen, M.H.; Force, T.; Ivy, S.P.; Leier, C.V.; Liu, G.; Lenihan, D.; Lindenfeld, J.; Maitland, M.L.; Remick, S.C.; Tang, W.H. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am. Heart J., 2012, 163(2), 156-163.
74. Gardner, B.M.; Pincus, D.; Gotthardt, K.; Gallagher, C.M.; Walter, P. Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb. Perspect. Biol., 2013, 5(3), a013169.
75. Schroder, M; Kaufman, R.J. The mammalian unfolded protein response. Annu. Rev. Biochem., 2005, 74, 739-789.
76. Franklin, S.; Pho, T.; Abreo, F.W.; Nassar, R.; De Benedetti, A.; Stucker, F.J.; Nathan, C.O. Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Arch. Otolaryngol. Head. Neck. Surg., 1999, 125(2), 177-182.
77. Crew, J.P.; Fuggle, S.; Bicknell, R.; Cranston, D.W.; de Benedetti, A.; Harris, A.L. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer., 2000, 82(1), 161-166.
78. Koumenis, C. ER stress; hypoxia tolerance and tumor progression. Curr. Mol. Med., 2006, 6(1), 55-69.
79. Han, J.; Back, S.H.; Hur, J.; Lin, Y.H.; Gildersleeve, R.; Shan, J.; Yuan, C.L.; Krokowski, D.; Wang, S.; Hatzoglou, M.; Kilberg, M.S.; Sartor, M.A.; Kaufman, R.J. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol., 2013, 15(5), 481-490.
80. Fribley, A.M.; Evenchik, B.; Zeng, Q.; Park, B.K.; Guan, J.Y.; Zhang, H.; Hale, T.J.; Soengas, M.S.; Kaufman, R.J.; Wang, C.Y. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J. Biol. Chem., 2006, 281(42), 31440-31447.
81. Wang Q.; Mora-Jensen H.; Weniger M.A.; Perez-Galan P.; Wolford C.; Hai T.; Ron D.; Chen W.; Trenkle W.; Wiestner A.; Ye, Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. PNAS, 2009, 106(7), 2200-2205.
82. Armstrong, J.L.; Flockhart, R.; Veal, G.J.; Lovat, P.E.; Redfern, C.P. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J. Biol. Chem., 2010, 285(9), 6091-6100.
83. Fribley, A.M.; Cruz, P.G.; Miller, J.R.; Callaghan, M.U.; Cai, P.; Narula, N.; Neubig, R.R.; Showalter, H.D.; Larsen, S.D.; Kirchhoff, P.D.; Larsen, M.J.; Burr, D.A.; Schultz, P.J.; Jacobs, R.R.; Tamayo-Castillo, G.; Ron, D.; Sherman, D.H.; Kaufman, R.J. Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response. J. Biomol. Screen., 2011, 16(8), 825-835.
84. Molinari, G. Natural products in drug discovery, present status and perspectives. Adv. Exp. Med. Biol., 2009, 655(13-27).
85. Flaherty, D.P.; Golden, J.E.; Liu, C.; Hedrick, M.; Gosalia, P.; Li, Y.; Milewski, M.; Sugarman, E.; Suyama, E.; Nguyen, K. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD), 2010.
86. Ou, H.D.; May, A.P.; O'Shea, C.C. The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication. Wiley. Interdiscip. Rev. Syst. Biol. Med., 2011, 3(1), 48-73.
87. Wimmer, R; Baccarini, M. Partner exchange, protein-protein interactions in the Raf pathway. Trends Biochem. Sci., 2010, 35(12), 660-668.
88. Erkizan, H.V.; Uversky, V.N.; Toretsky, J.A. Oncogenic partnerships, EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin. Cancer. Res., 2010, 16(16), 4077-4083.
89. Fuentes, G.; Oyarzabal, J.; Rojas, A.M. Databases of protein-protein interactions and their use in drug discovery. Curr. Opin. Drug. Discov. Devel., 2009, 12(3), 358-366.
90. Pietsch, E.C.; Sykes, S.M.; McMahon, S.B.; Murphy, M.E. The p53 family and programmed cell death. Oncogene, 2008, 27(50), 6507-6521.
91. LaCasse, E.C.; Mahoney, D.J.; Cheung, H.H.; Plenchette, S.; Baird, S.; Korneluk, R.G. IAP-targeted therapies for cancer. Oncogene. 2008, 27(48), 6252-6275.
92. Iyer N.G.; Ozdag H.; Caldas C. p300/CBP and cancer. Oncogene, 2004, 23(24), 4225-4231.
93. Arkin, M. Protein-protein interactions and cancer, small molecules going in for the kill. Curr. Opin. Chem. Biol., 2005, 9(3), 317-324.
94. Fry, D.C.; Vassilev, L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med., 2005, 83(12), 955-963.
95. Lee, L.W.; Mapp, A.K. Transcriptional switches, chemical approaches to gene regulation. J. Biol. Chem., 2010, 285(15), 11033-11038.
96. Patury, S.; Miyata, Y.; Gestwicki, J.E. Pharmacological targeting of the Hsp70 chaperone. Curr. Top. Med. Chem., 2009, 9(15), 1337-1351.
97. Berg, T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr. Top. Microbiol. Immunol. 2011, 348, 139-149.
98. Park, C.M; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K.C.; Nimmer, P.; Shoemaker, A.R.; Song, X.; Tahir SK, Tse C, Wang X, Wendt MD, Yang X, Zhang H, Fesik SW, Rosenberg SH, Elmore SW. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem., 2008, 51(21), 6902-6915.
99. Shoemaker, A.R.; Mitten, M.J.; Adickes, J.; Ackler, S.; Refici, M.; Ferguson, D.; Oleksijew, A.; O'Connor, J.M.; Wang, B.; Frost, D.J.; Bauch, J, Marsh, K, Tahir, S.K, Yang, X, Tse, C, Fesik, S.W, Rosenberg, S.H, Elmore, S.W. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res., 2008, 14(11), 3268-3277.
100. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L, Tahir, S.K, Xiao, Y, Yang, X, Zhang, H, Fesik, S, Rosenberg, S.H, Elmore, S.W. ABT-263, a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res., 2008, 68(9), 3421-3428.
101. Zinzalla, G.; Thurston, D.E. Targeting protein-protein interactions for therapeutic intervention, a challenge for the future. Future Med. Chem., 2009, 1(1), 65-93.
102. Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions, progressing towards the dream. Nat. Rev. Drug Discov., 2004, 3(4), 301-317.
103. Cochran, A.G. Antagonists of protein-protein interactions. Chem. Biol., 2000, 7(4), R85-R94.
104. Jochim, A.L.; Arora, P.S. Systematic analysis of helical protein interfaces reveals targets for synthetic inhibitors. ACS Chem. Biol., 2010, 5(10), 919-923.
105. De Guzman, R.N.; Goto, N.K.; Dyson, H.J; Wright, P.E. Structural basis for cooperative transcription factor binding to the CBP coactivator. J. Mol. Biol., 2006, 355(5), 1005-1013.
106. Novatchkova, M.; Eisenhaber, F. Linking transcriptional mediators via the GACKIX domain super family. Curr. Biol., 2004, 14(2), R54-R55.
107. Goto, N.K.; Zor, T.; Martinez-Yamout, M.; Dyson, H.J.; Wright, P.E. Cooperativity in transcription factor binding to the coactivator CREBbinding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain. J. Biol. Chem., 2002, 277(45), 43168-43174.
108. Campbell, K.M.; Lumb, K.J. Structurally distinct modes of recognition of the KIX domain of CBP by Jun and CREB. Biochemistry, 2002, 41(47), 13956-13964.
109. Zor, T.; De Guzman, R.N.; Dyson, H.J.; Wright, P.E. Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. J. Mol. Biol., 2004, 337(3), 521-534.
110. Alluri, P.; Liu, B.; Yu, P.; Xiao, X.; Kodadek, T. Isolation and characterization of coactivator-binding peptoids from a combinatorial library. Mol. BioSyst., 2006, 2(11), 568-579.
111. Best, J.L.; Amezcua, C.A.; Mayr, B.; Flechner, L.; Murawsky, C.M.; Emerson, B.; Zor, T.; Gardner, K.H.; Montminy, M. Identification of small-molecule antagonists that inhibit an activator, coactivator interaction. PNAS, 2004, 101(51), 17622-17627.
112. Frangioni, J.V.; LaRiccia, L.M.; Cantley, L.C.; Montminy, M.R. Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening. Nat. Biotechnol., 2000, 18(10), 1080-1085.
113. Bates, C.A.; Pomerantz, W.C.; Mapp, A.K. Transcriptional tools, Small molecules for modulating CBP KIX-dependent transcriptional activators. Biopolymers, 2011, 95(1), 17-23.
114. Li, B.X.; Xiao, X. Discovery of a small-molecule inhibitor of the KIXKID interaction. Chembiochem, 2009, 10(17), 2721-2724.
115. Buhrlage, S.J.; Bates, C.A.; Rowe, S.P.; Minter, A.R.; Brennan, B.B.; Majmudar, C.Y.; Wemmer, D.E.; Al-Hashimi, H.; Mapp, A.K. Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. ACS Chem. Biol., 2009, 4(5), 335-344.
116. Majmudar, C.Y.; Hojfeldt, J.W.; Arevang, C.J.; Pomerantz, W.C.; Gagnon, J.K.; Schultz P.J.; Cesa L.C.; Doss C.H.; Rowe S.P.; Vasquez V.; Tamayo-Castillo, G.; Cierpicki, T.; Brooks, C.L. 3rd.; Sherman, D.H.; Mapp, A.K. Sekikaic acid and lobaric acid target a dynamic interface of the coactivator CBP/p300. Angew. Chem. Int. Edit., 2012, 51(45), 11258-11262.